Short-course CT online-adaptive radiotherapy for post-operative endometrial cancer
Official title: Short-course Hypofractionated Online-adaptive Radiotherapy for the Treatment of ENdometrial Cancer
Run by Royal Marsden NHS Foundation Trust · NCT07675733 · Data updated 2026-11-12
This trial tests whether delivering post-operative radiotherapy in 5 sessions using CT online-adaptive radiotherapy is safe and feasible for endometrial cancer patients.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 30 (estimated) |
| Sponsor | Royal Marsden NHS Foundation Trust Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Sutton) |
| Status | Recruiting |
| Started | September 11, 2026 |
| Main results expected | July 2028 |
| Study ends | July 2030 |
| Registry record updated | October 28, 2026 |
| Trial ID | NCT07675733 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with histologically confirmed endometrial carcinoma, fully resected disease, and indication for post-operative EBRT, who are/functionally eligible per ECOG 0–2 and other criteria.
✕Probably not a fit
Patients with contraindications to higher-dose per-fraction radiotherapy or who experience unexpected toxicity may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional trial investigates a shortened radiotherapy course for endometrial cancer using CT-based online-adaptive radiotherapy (CT-OART). The approach redefines targets and replans daily while the patient stays on the treatment couch, with a regimen of 30 Gy in 5 fractions over about 10–11 days. The study seeks to determine if the hypofractionated schedule can be delivered safely and feasibly compared with traditional longer courses. Eligible participants are adults with resected high-intermediate to high-risk disease who require post-operative EBRT, with certain allowances for prior chemotherapy or brachytherapy timing. The Royal Marsden NHS Foundation Trust leads the study at its Sutton location.
Why it matters
Potential benefit: If successful, patients could receive effective post-operative radiotherapy in a shorter time frame with potentially similar control and reduced treatment burden.
How similar studies have gone: Previous approaches using adaptive radiotherapy have shown feasibility in other gynecologic cancers, though ultra-hypofractionation with CT-OART in endometrial cancer is novel and exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria 1. Histologically confirmed endometrial carcinoma - inclusive of endometrioid adenocarcinoma, carcinosarcoma, clear cell carcinoma, serous carcinoma, dedifferentiated carcinoma, mucinous carcinoma, mixed carcinoma 2. Age greater than 18 years old 3. Disease fully resected at time of surgery 4. Indication for post-operative external beam radiotherapy: high-intermediate risk and high-risk disease (ESGO-ESTRO-ESP guideline), or at the discretion of treating Clinical Oncologist 5. If adjuvant systemic chemotherapy is indicated, participants will still be eligible for trial participation, provided there is a minimum 3-week gap between completing chemotherapy and beginning external beam radiotherapy 6. If adjuvant vaginal vault brachytherapy boost is indicated, participants will still be eligible for trial participation, with a minimum gap of 1 day from completion of external beam radiotherapy to first fraction of brachytherapy 7. WHO Performance Status 0 - 2 8. Informed written consent Exclusion criteria 1. Previous pelvic radiotherapy 2. Contraindication to receiving external beam radiotherapy 3. Residual disease identified on post-operative imaging 4. FIGO 2023 Stage 3C2 disease requiring extended para-aortic treatment field 5. Hip prostheses or other metal work within the imaging field which would produce significant imaging artifact 6. Indication for adjuvant concurrent chemo-radiotherapy
Where it's running
-
The Royal Marsden Hospital - Sutton
Sutton, United Kingdom Recruiting
Study contacts
- Principal investigator: Susan Lalondrelle, Consultant Clinical Oncologist — Royal Marsden NHS Foundation Trust
- Study coordinator: Benjamin Thomas, Clinical Research Fellow
- Email: SHORTEN.trial@rmh.nhs.uk
- Phone: +442086426011
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prognosis and Therapy Clues in High-Risk, Non-Invasive Endometrial Cancer
This study looks at people with non-invasive endometrial cancer that has high-risk molecular features to see how often lymph nodes are involved and how often the cancer comes back or affects survival after different adjuvant treatments.
-
GV20-0251 treatment for adults with advanced solid tumors
This study will test GV20-0251 to see if it helps adults with advanced solid tumors that have stopped responding to approved therapies.
-
Using metabolomic profiling to screen for endometrial cancer
This study is testing a new way to use blood samples to see if certain markers can help identify endometrial cancer in women compared to other types of growths and cancers.
-
GV20-0251 treatment for advanced solid tumors
This study is testing a new treatment called GV20-0251 for people with advanced solid tumors that haven't improved with standard treatments, to see how safe it is and if it works better when combined with another medication.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.